Smitherman AB / Ligand / Taylor AE / CaP / PET / Ford / Cox / Hess / /
Country
United States / /
Currency
pence / / /
Event
FDA Phase / /
Facility
Roswell Park Cancer Institute / terminal SREBP / /
IndustryTerm
treatment of castration-resistant prostate cancer / molecular machinery / Prostate Cancer Treatment / food / tissue-specific transcriptional network / treatment of advanced prostate cancer / basal transcriptional machinery / model systems / food intake / therapy for prostate cancer / /
MedicalCondition
glaucoma / androgen-independent prostate cancer / Endocr Relat Cancer / recurrent prostate cancer / non-organ confined prostate cancer / metastatic prostate cancer / symptomatic hormone-resistant prostate cancer / castration-resistant prostate cancer / metastatic prostate cancer tumors / antiandrogen withdrawal syndrome / human cancers / heterogeneous disease / hormone-refractory adenocarcinoma / J Cancer / metastatic castration-resistant prostate cancer / prostatic cancer / obesity / castration-resistant tumor / prostate cancer / hormone-refractory prostate cancer / metastatic hormone-refractory prostate cancer / leukemia / tumor / megakaryoblastic leukemia / advanced prostate cancer / Cancer / disease / atherosclerosis / Castration-recurrent prostate cancer / endocrine-therapy-resistant human prostate cancer / metastatic carcinoma / mone-refractory prostate cancer / human prostate cancer / aggressive and lethal disease / chronic disease / androgen-refractory prostate cancer / /
MedicalTreatment
chemotherapy / prostatectomy / CCR / /
Organization
National Institute of Health / Center for Pharmacology and Genetics / food and drug administration / Androgen Response Unit / NCI / Department of Defense Prostate Cancer Research Program / FDA / Roswell Park Cancer Institute / /
Int. J. Biol. Sci. 2014, Vol. 10 Ivyspring International Publisher 576